Edgewise Therapeutics, Inc. (EWTX) Stock: Price, Forecast & Analyst Target
Edgewise Therapeutics, Inc. (EWTX) — MoonshotScore 66/100 (Strong band), calculated Oct 5, 2026. Price $40.30 (-2.66%), as of the Oct 5, 2026 trading session; market cap $4.34B. Expected results Nov 5, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 9.42× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Nov 5, 2026
Edgewise Therapeutics, Inc. · EWTX · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Edgewise is developing small-molecule treatments for rare muscle diseases, with its lead program addressing the genetic causes of Duchenne and Becker muscular dystrophy. The company has cleared its initial clinical phase and now faces the fundamental question that defines pre-commercial biotech: whether the science that works in the lab translates to patient outcomes in later trials. Cash reserves are substantial, but the company has never generated revenue from its therapeutic candidates.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Edgewise Therapeutics (EWTX)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but stalling growth; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Surging.
- quarterly revenue $0 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 5 of 8
- Altman Z 82.39 · Piotroski F 1
Holding back: soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 64 | Fair | |
| 65 | Fair | |
| 64 | Fair | |
| 64 | Fair | |
| 65 | Strong | |
| 65 | Strong |
The score was 66 in the stored Oct 4, 2026 snapshot and remains 66 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $40.30 | |
| Change on the day | -2.66% | |
| 52-week range | $14.25 – $48.51 | |
| Market capitalisation | $4.34B | |
| Price / earnings (trailing) | -13.09 | |
| Shares traded on the day | 1.58M | |
| Beta (volatility vs the S&P 500) | 0.28 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Edgewise Therapeutics (EWTX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Oct 1, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the EWTX film — every key number, told as a short cinematic story
~2 min · open the film
What is Edgewise Therapeutics (EWTX), and what does it report?
Short answer · as of
Edgewise operates as a precision medicine company, engineering compounds designed to modulate key muscle proteins in patients with specific genetic conditions.
Research dated 2026-09-13.
Edgewise operates as a precision medicine company, engineering compounds designed to modulate key muscle proteins in patients with specific genetic conditions. The company generates no product revenue; its financials measure only research spending, which expanded significantly as the lead candidate progressed through early-stage clinical work. The core business model assumes future licensing or commercialization opportunities, with analyst expectations building in revenue inflection points well into the next cycle.
What do the latest results show for Edgewise Therapeutics (EWTX)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0.
Research dated 2026-09-13.
The most recent quarter shows losses widening from the prior period as research and development spending accelerated. This trend follows the expected pattern for companies in clinical development: burn rate increases when a program moves deeper into testing. The latest earnings reports show management's cost structure remains disciplined relative to cash resources, with R&D intensity expanding while general and administrative expenses stayed modest in absolute terms.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · R&D
- $47.55M Jun 30, 2026
- Latest quarter · SG&A
- $14.39M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$61.94M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | $47.55M | $14.39M | −$61.94M |
| Mar 31, 2026 | Not available | $42.65M | $11.46M | −$54.12M |
| Dec 31, 2025 | Not available | $43.59M | $12.38M | −$55.98M |
| Sep 30, 2025 | Not available | $37.48M | $9.38M | −$46.86M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · EPS vs estimate
- Below estimate Aug 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 6, 2026 | Not available | Not available | −$0.5300 | −$0.4677 |
| May 7, 2026 | Not available | Not available | −$0.4600 | −$0.5000 |
| Feb 26, 2026 | Not available | Not available | −$0.4700 | −$0.4300 |
| Nov 6, 2025 | Not available | Not available | −$0.3900 | −$0.4000 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$57M | -$0.53 (diluted) |
| Q1 FY2026 | $0 | -$49M | -$0.46 (diluted) |
| Q4 FY2025 | $0 | -$50M | -$0.49 (diluted) |
| Q3 FY2025 | $0 | -$41M | -$0.39 (diluted) |
What are the financial strengths and risks for Edgewise Therapeutics (EWTX)?
Short answer
Cash and short-term investments were $460.71M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$43.51M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
The company's financial position is characterized by a large cash balance relative to current burn rate, though the cash runway depends entirely on whether development timelines extend. Balance sheet risk is low; debt is minimal and liquidity ratios reflect strong defensive positioning. The central vulnerability is clinical: if efficacy or safety questions emerge in later trials, the valuation multiple would face significant pressure regardless of cash sufficiency. Institutional ownership has grown, suggesting confidence among sophisticated investors in the underlying science.
Data-derived red flags
- Negative return on equity (-39.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$43.51M Jun 30, 2026
- Previous quarter · operating cash flow
- −$42.54M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$43.51M | −$30,000 |
| Mar 31, 2026 | −$42.54M | −$260,000 |
| Dec 31, 2025 | −$38.59M | $180,000 |
| Sep 30, 2025 | −$34.78M | −$90,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Edgewise Therapeutics (EWTX)?
Short answer · as of
The next earnings report is expected on Nov 5, 2026.
Research dated 2026-09-13.
Readers should track clinical milestones closely, particularly data readouts that would confirm efficacy in the target indication. Analyst estimates currently assume the company will reach revenue-generating status, and interim trial results will either validate or challenge those projections. Management has signaled timelines for upcoming data presentations; watch whether results match the expectations embedded in analyst price targets. Cash runway at current burn rates provides cushion, but extended development timelines would require capital raises that could dilute shareholders.
How does Edgewise Therapeutics compare with its peers?
Short answer
Edgewise Therapeutics's score ranks tied for 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Compared with other pre-commercial biotechs developing treatments for rare genetic muscle diseases, Edgewise's differentiation rests on its mechanism—modulation of muscle proteins rather than gene therapy—and the specificity of its patient population. Other companies in the space pursue different molecular targets or broader disease indications; this company's narrower focus trades off market size for reduced development complexity. Analyst ratings are more favorable than the sector median, reflecting confidence in the approach, though that confidence remains conditional on clinical proof.
| Company | Price | Market value | Score |
|---|---|---|---|
| $39.92 Oct 5, 2026 | $2.31B | 98 5-pillar Oct 5, 2026 | |
| $46.52 Oct 5, 2026 | $3.71B | 96 5-pillar Oct 5, 2026 | |
| $306.77 Oct 5, 2026 | $6.15B | 96 5-pillar Oct 5, 2026 | |
| $10.16 Oct 5, 2026 | $2.35B | 94 5-pillar Oct 5, 2026 | |
| $27.11 Oct 5, 2026 | $2.41B | 92 5-pillar Oct 5, 2026 | |
| $25.15 Oct 5, 2026 | $3.15B | 88 5-pillar Oct 5, 2026 | |
| $20.11 Oct 5, 2026 | $3.44B | 76 5-pillar Oct 5, 2026 | |
| $46.97 Oct 2, 2026 | $3.36B | 73 5-pillar Oct 5, 2026 | |
| $58.73 Oct 5, 2026 | $2.80B | 70 5-pillar Oct 5, 2026 | |
| $159.73 Oct 5, 2026 | $6.40B | 69 5-pillar Oct 5, 2026 | |
| $84.38 Oct 5, 2026 | $5.09B | 68 5-pillar Oct 5, 2026 | |
| Edgewise Therapeutics (EWTX) — this page | $40.30 | $4.34B | 66 |
| $27.48 Oct 5, 2026 | $3.06B | 66 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $36.00 – $66.00
- Consensus target
- $53.10
- Median target
- $52.00
Consensus record · Captured .
Measured against a quoted price of $40.30 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 60
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 19
- Other transactions
- 41
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 238 Period end Jun 30, 2026
- Previous quarter · holders
- 225 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Orbimed Advisors LLC | 15,518,492 |
| Paradigm Biocapital Advisors LP | 10,215,455 |
| Ra Capital Management, L.P. | 8,392,730 |
| Blackrock, INC. | 6,606,336 |
| Jupiter Topco LLC | 6,075,331 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Edgewise Therapeutics (EWTX)?
- Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
- Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says
- Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
- Edgewise Therapeutics Says Preclinical Data Show Hypertrophic Cardiomyopathy Candidate EDG-7500 Improves Cardiac Relaxation While Preserving Pumping Function
Common Questions About EWTX (Healthcare)
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is the lead oral dystrophinopathy treatment?
The lead program is an orally administered compound engineered to address the genetic causes of dystrophinopathies, a family of muscle-wasting disorders. The drug's design targets a specific molecular pathway rather than attempting whole-gene replacement, which may offer practical advantages in patient administration and manufacturing scalability.
Does the company have enough cash to reach clinical milestones?
Cash reserves cover current burn rates across multiple years, providing sufficient runway for the planned clinical program progression. The company's burn trajectory has remained relatively controlled, with spending increases tied to trial expansion rather than cost inflation. Whether this proves adequate depends on whether development timelines extend beyond current expectations.
Why do analysts expect revenue to start so far in the future?
Analyst projections assume the company must complete later-stage clinical trials, obtain regulatory approval, and establish commercial infrastructure before generating meaningful product sales. For rare-disease biotechs, this sequence typically spans multiple years of development. Analyst estimates reflect the typical clinical-stage risk curve rather than confidence in a near-term inflection point.
Are company insiders buying or selling the stock?
Recent insider activity shows share dispositions that appear consistent with equity compensation vesting rather than opportunistic purchases. No recent buy signals from management were reported; insider transactions are concentrated in awards and exemptions typical of pre-commercial biotech organizations where equity serves as the primary compensation lever.
What is the EWTX stock price today?
The last price recorded on this page for Edgewise Therapeutics, Inc. (EWTX) is $40.30, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the EWTX price target?
The analyst consensus price target for Edgewise Therapeutics, Inc. (EWTX) is $53.10 (range $36.00 to $66.00, median $52.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (67 figures)
The 67 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | Boulder, CO | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "1715 38th Street, Boulder, CO, 80301, US". |
FMP — 58 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 5, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $40.30 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:44:51.987Z. | |
px.change | Change on the day | -2.66% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $4.34B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:01.000Z. Captured from FMP at 2026-10-05T21:44:51.009Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$1.10 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | -13.09 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.58M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.28 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Kevin Koch | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.founder | Founder named in the filing | Peter A. Thompson FACP — Co-Founder & Independent Chairman | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 127 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $0.00, net result −$42.81M; FY2022 revenue $0.00, net result −$67.64M; FY2023 revenue $0.00, net result −$100.16M; FY2024 revenue $0.00, net result −$133.81M; FY2025 revenue $0.00, net result −$167.79M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $47.55M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $14.39M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$61.94M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $42.65M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $11.46M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$54.12M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $43.59M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $12.38M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$55.98M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $37.48M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $9.38M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$46.86M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-06.eps_actual | EPS · reported — report date 2026-08-06 | −$0.5300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_estimated | EPS · estimate — report date 2026-08-06 | −$0.4677 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | −$0.4600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | −$0.5000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.eps_actual | EPS · reported — report date 2026-02-26 | −$0.4700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.eps_estimated | EPS · estimate — report date 2026-02-26 | −$0.4300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.eps_actual | EPS · reported — report date 2025-11-06 | −$0.3900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-06.eps_estimated | EPS · estimate — report date 2025-11-06 | −$0.4000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $460.71M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$43.51M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $3.59M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 9.95× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$43.51M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$42.54M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$30,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$260,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$38.59M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | $180,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$34.78M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$90,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $36.00 – $66.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $53.10 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $52.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 60 transactions · 0 purchases, 19 sales, 41 other transactions · 8 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 238 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 225 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Orbimed Advisors LLC — shares in provider snapshot | 15,518,492 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Paradigm Biocapital Advisors LP — shares in provider snapshot | 10,215,455 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Ra Capital Management, L.P. — shares in provider snapshot | 8,392,730 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Blackrock, INC. — shares in provider snapshot | 6,606,336 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Jupiter Topco LLC — shares in provider snapshot | 6,075,331 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 82.39 · Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $14.25 – $48.51 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -39.0% · ROA -41.1% · current ratio 16.24 · earnings yield -4.5% · free-cash-flow yield -3.7% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 9.42× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $460.71M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-06.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.5300) with the recorded estimate (−$0.4677) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 66 of 100 · Strong · pillars 43 / 95 / 50 / 22 / 92 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 66 (stored snapshot Oct 4, 2026) → 66 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-06. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-06.eps_actual.comparison,earn.history.depth.2026-08-06.eps_actual,earn.history.depth.2026-08-06.eps_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-02-26.eps_actual,earn.history.depth.2026-02-26.eps_estimated,earn.history.depth.2025-11-06.eps_actual,earn.history.depth.2025-11-06.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| SEC Central Index Key | 0001710072 | 2026-09-13 | OFFICIAL | SEC EDGAR filer record |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $460.70M; Cash and short-term investments: $460.70M; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $457.10M; Total debt: $3.60M; Cash and investments: $460.70M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Institutional ownership (13F) | Holders: 238; Quarter: 2026-06-30; Holders previous quarter: 225 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Next earnings report | Date: 2026-11-05; EPS estimate: -$0.55 per share; Revenue estimate: $129.17M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Recent SEC filings |
| 2026-08-06 | OFFICIAL | SEC EDGAR filer submissions |
| Analyst actions, most recent per firm | Captured record · 10 entries
One row per firm — the firm's most recent action in our feed. Other data vendors may carry firms ours does not. | 2026-08-20 | FMP | Financial Modeling Prep (FMP) analyst grades |
| Largest 5 institutional holders | Captured record · 5 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $460.70M; Decline: $31.80M; Opening balance: $492.50M; Average change per period: $4.50M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Most recent periodic reports | Annual: Document: https://www.sec.gov/Archives/edgar/data/1710072/000110465926020112/ewtx-20251231x10k.htm, Filed: 2026-02-26, Period end: 2025-12-31; Quarterly: Document: https://www.sec.gov/Archives/edgar/data/1710072/000110465926091670/ewtx-20260630x10q.htm, Filed: 2026-08-06, Period end: 2026-06-30 | 2026-08-06 | OFFICIAL | SEC EDGAR filer submissions |
| Insider transactions, last 180 days | Net shares: 1,262,675; Window days: 180; Price low: $0.18; Clustered days: 2026-08-12; Price high: $44.52; Buy transactions: 0; Distinct insiders: 7; Sell transactions: 19; Other transactions: 41; Total transactions: 60; Other transaction types: A-Award: 18, M-Exempt: 23; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-08-13 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
| Named officers | CEO: Kevin Koch; Officers: Aylin Tugcu — Title: Senior Vice President of Cardiovascular Clinical Development & Medical Affairs; Kevin Koch — Title: President, Chief Executive Officer & Director, Pay: $1.15M, Born: 1960; Peter A. Thompson FACP — Title: Co-Founder & Independent Chairman, Pay: $80,000, Born: 1960; John R. Moore — Title: General Counsel, Born: 1964; Michael Nofi — Title: Chief Financial Officer, Pay: $97,700, Born: 1971; Alan J. Russell — Title: Co-Founder, Chief Scientific Officer & Director, Pay: $737,866, Born: 1970; Badreddin Edris — Title: Co-Founder & Independent Director, Pay: $55,000, Born: 1987; Behrad Derakhshan — Title: Chief Operating Officer, Pay: $803,100, Born: 1980 Titles and pay come from the company's proxy statement as our provider parsed it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) |
| Most recent Schedule 13D | Form: SC 13D/A; Filed: 2024-11-12 A Schedule 13D is filed by a holder of more than 5% who is not a passive investor. | 2024-11-12 | OFFICIAL | SEC EDGAR — SC 13D/A |
Data provided for informational purposes only.